Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Clin Nephrol
Watch the Recording What Youll Learn Current payer perspectives on GLP-1 coverage for obesity treatment and type 2 diabetes management Emerging affordability thresholds and price sensitivity among plans Strategies for addressing off-label type 2 diabetes GLP-1 use and its financial impact Approaches to prior authorization protocols and BMI requirements for obesity GLP-1s The role of weight management vendors in comprehensive obesity GLP-1 coverage strategies Market insights on compounded GLP-1 products and their place in benefit design Attendees will gain actionable strategies and insights to optimize their pharmacy benefit design for these high-impact medications in 2025 and beyond
Im Gegensatz zum AVP ist die gebruchliche UVP eine Empfehlung der Hersteller
In a randomized phase 3a study published in Diabetes Care, those taking oral semaglutide monotherapy experienced superior and clinically significant improvements in A1c and weight loss compared to those taking a placebo
US$ 24.92
US$ 22.55
US$ 26.21
US$ 29.34
US$ 25.78
US$ 27.14
US$ 23.47
